AusperBio Therapeutics Introduces Novel AHB-137 for Chronic Hepatitis B Treatment
AusperBio Therapeutics has introduced AHB-137, a groundbreaking treatment for chronic hepatitis B (CHB).
With approximately 296 million people globally affected by chronic HBV and limited treatment options for a cure, the disease is a major cause of liver cancer.
AHB-137, developed using AusperBio's proprietary Moed-Oligo™ antisense oligonucleotide (ASO) technology, aims to achieve a functional cure for chronic hepatitis B.
The innovative ASO, which employs a dual-mechanism approach, showed promising preclinical results that were showcased at the 2023 EASL™ conference. Currently, AHB-137 is advancing through concurrent phase 1b and phase 2 trials at multiple international sites.
Chronic hepatitis B is a serious liver disease impacting nearly 290 million people worldwide and leading to severe conditions like liver cirrhosis and hepatocellular carcinoma.
While existing treatments can manage HBV replication, a true cure remains elusive. The development of AHB-137 reflects a critical step toward addressing this urgent medical need and improving CHB treatment options.
